SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending due to renewed interest in privacy coins and speculation around its upcoming halving event, with some community members suggesting it could outperform Bitcoin. Discussions highlight its limited supply and potential as a hedge against broader market volatility. Some believe it could even rival Bitcoin's dominance due to its privacy features.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy ($PRO) is trending amidst fluctuating price action, leading to mixed sentiments within the community. Discussions revolve around identifying potential entry points, with some traders expressing frustration over recent price movements and questioning the project's short-term potential, while others remain optimistic about Propy's long-term vision in real estate tokenization and RWA.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPT is trending as investors anticipate clarity on Elevidys rollout and updated guidance during the upcoming earnings call, with specific attention to patient volume and non-ambulatory progress. The community is speculating on FDA clarity, potential global rollout, and the possibility of beating top and bottom line expectations, while also weighing milestone payments and one-time charges impacting near-term profits. Overall, investors are focused on management's tone and execution to restore trust and potentially unlock significant upside.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending due to potential synergies with ExxonMobil, specifically in carbon capture technology for data centers, sparking community excitement. The community is closely monitoring the potential impact of these collaborations, especially after ExxonMobil's conference call and the surge in volume late in the day. The focus remains on whether FCEL's technology will be instrumental in ExxonMobil's carbon capture initiatives, given their past partnership and the increasing demand for clean energy solutions.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

DIS is trending amid discussions around recent price hikes for its streaming services and the integration of Hulu into Disney+, impacting subscriber counts and revenue strategies. Community members are debating the influence of political controversies and potential shifts in content strategy, while analysts weigh in on the stock's long-term growth potential and ongoing volatility. There's also buzz around the possibility of mergers and acquisitions and some debate about the quality and quantity of content available on the platform.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor ($TAO) is trending as the community highlights its potential in decentralized AI, with discussions around its unique role, upcoming halving, and exchange-traded product (ETP) anticipation. Community members are actively discussing staking yields and subnet opportunities within the Bittensor network, pointing towards real utility. TAO's position as a decentralized AI infrastructure platform aiming to challenge AI centralization is also driving interest.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending as traders weigh the impact of OPEC+'s decision on production levels and potential acquisition scenarios for the company. Community discussions revolve around whether the stock is undervalued and poised for a breakout, or if it will remain range-bound without a buyout. Bullish investors highlight the company's financial strength and potential for long-term growth, while others express frustration with its recent performance.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power is trending due to Vanguard's recent disclosure of a significant stake in the company, signaling institutional confidence in its long-term potential. Community discussions revolve around the implications of this investment, especially alongside existing partnerships with Samsung and BMW, and the overall prospects for solid-state battery technology. Despite some skepticism regarding the stage of commercialization, investors are closely watching SLDP as a key player in the evolving EV battery landscape.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

LEU is trending amid renewed interest in nuclear energy and uranium, especially with discussions around government support and potential deals. Community members are actively discussing the stock's technicals, potential for a short squeeze given its low float, and long-term growth prospects related to AI-driven data center power needs. A recent analyst upgrade and positive industry outlook are also contributing to the heightened interest.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the community discusses recent Airbus deliveries and a substantial Vietjet Air engine order. Investor sentiment is largely positive, with some anticipating new SMR orders and analysts revising forecasts upwards. Discussions also include the potential for Rolls-Royce to power new data centers and collaborate on future aircraft engine projects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Metsera Issues Statement in Response to Litigation

Metsera Issues Statement in Response to Litigation Metsera Issues Statement in Response to Litigation PR Newswire NEW YORK, Oct. 31, 2025 NEW YORK, Oct. 31, 2025 /PRNewswire/ -- Metsera, Inc...

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...

Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results?

Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Amazon & Apple Lift Sentiment, Nvidia Hopes to Sell China Blackwell Chips  The Opening Trade 10/31

US stock futures advanced after strong earnings from Amazon and Apple. Amazon surged 12% in premarket trading on its fastest cloud-unit growth in nearly three years, while Apple gained on a revenue...

<ul class="summary-bullets"><li>VKTX shares&nbsp;have surged&nbsp;about 45% in October,&nbsp;set for their strongest monthly gain of 2025.</li><li>Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.</li><li>Pfizer’s stalled Metsera deal and past struggles with its own obesity program added to speculation that Viking could become a future acquisition target.</li></ul>Viking Therapeutics shares have climbed nearly 45%&nbsp;in October, putting the stock on track for its best monthly performance of 2025, as investor excitement builds over its experimental obesity treatment and renewed analyst optimism.<h2 class="st-heading-2">Canaccord Starts Coverage With ‘Buy’&nbsp;</h2>Viking&nbsp;shares have rallied&nbsp;amid a slew of bullish analyst calls on Wall Street following quarterly earnings, with&nbsp;the latest coming from Canaccord Genuity’s initiation on Wednesday with a ‘Buy’ rating and $106 price target, representing an upside of 178% from the stock’s last close. The brokerage firm said Viking stands out as a leader in the obesity drug development space, citing its strong Phase 2 efficacy data from August for the oral version of VK2735.Canaccord expects readouts from Viking’s two Phase 3 trials in 2027 and mid-2028, and believes VK2735 can differentiate on multiple fronts in a crowded obesity drug pipeline.<h2 class="st-heading-2">Pfizer And Novo Nordisk Fuel M&amp;A Speculation</h2><a href="https://stocktwits.com/news-articles/markets/equity/retail-investors-expect-viking-therapeutics-to-bag-deal/cLGFym0R3xj">Investor chatter also intensified</a> after Novo Nordisk submitted an unsolicited proposal to acquire Metsera, a company that Pfizer had already agreed to purchase in September.Metsera has given Pfizer four business days to adjust its offer, fueling speculation among traders on Stocktwits that Pfizer might turn its attention to Viking if its Metsera deal falls through. Pfizer discontinued its own oral weight-loss candidate, Danuglipron, in April 2025, following safety issues, and has been seeking other ways to re-enter the obesity market.<h2 class="st-heading-2">Viking’s Obesity Drug Program</h2>Viking is developing VK2735, a dual agonist of the GLP-1 and GIP receptors, both of which play key roles in regulating glucose, appetite, and body weight. The company is testing subcutaneous and oral versions of the therapy in clinical trials.Early-stage data have shown positive safety and efficacy signals, reinforcing Wall Street’s belief that Viking could become a meaningful player in the weight-loss drug race dominated by Novo Nordisk and Eli Lilly.<h2 class="st-heading-2">Q3 Earnings And Outlook</h2>Viking Therapeutics reported a net loss of $52.3 million for the third quarter, in line with expectations, as it continues to invest heavily in its obesity and metabolic disease pipeline. Viking said it plans to meet with the U.S. Food and Drug Administration (FDA) by year-end to discuss advancing the oral formulation into late-stage clinical trials.The company noted that Phase III enrollment for its injectable version of VK2735 remains ahead of schedule, with completion expected in early 2026. A maintenance dosing study is currently underway to assess how best to sustain weight loss over time.&nbsp;Viking also plans to file an Investigational New Drug (IND) application with the FDA in the first quarter of 2026 for its next program targeting the amylin receptor, a mechanism that could complement GLP-1 and GIP therapies by improving appetite control and weight regulation.<h2 class="st-heading-2">Stocktwits Users See Viking At Center Of Pfizer–Novo Rivalry&nbsp;</h2>On Stocktwits, retail sentiment for Viking was ‘extremely bullish’ amid a 200% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:969/139;" src="https://news.stocktwits-cdn.com/vktx_ss_jpg_85eeea1fb9.webp" alt="vktx ss.jpg" width="969" height="139"><figcaption>VKTX sentiment and message volume as of October 31 | Source: Stocktwits</figcaption></figure>Some traders speculated that Novo Nordisk’s renewed bid for Metsera may be tied to competitive pressure from Viking’s obesity program. One bullish user&nbsp;<a href="https://stocktwits.com/biolover/message/634429740">suggested</a> Novo’s main interest in Metsera is its early-stage oral GLP-1/GIP agonist, adding that Novo knows Viking’s oral 2735 could be a long-term threat.<stembedurl>https://stocktwits.com/biolover/message/634429740</stembedurl>Another trader&nbsp;<a href="https://stocktwits.com/Bagholding_VKTX/message/634425707">agreed</a>,&nbsp;speculating Novo may have approached Viking before turning to Metsera, but “panicked” once Pfizer entered the picture. The user added that institutional investors may share the same view, noting Viking’s strong price reaction.<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/634425707</stembedurl><a href="https://stocktwits.com/symbol/VKTX">Viking’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Equity

Mizuho's Holtz talks what is behind Novo's bid for Metsera

Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat...

Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages GES, MTSR, TGNA, CYBR Shareholders to Contact the Firm to...

<ul class="summary-bullets"><li>Novo Nordisk announced on Thursday that it has submitted an unsolicited proposal to acquire Metsera, following Pfizer's agreement to acquire the smaller obesity biopharmaceutical company in September.</li><li>Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients.</li><li>The company is now looking to enter the booming obesity market with an acquisition. &nbsp;</li></ul>Retail investors on Stocktwits expect Pfizer to make an acquisition bid for Metsera’s rival, Viking Therapeutics, as the company’s agreed-upon deal with Metsera hangs in limbo.Danish drugmaker Novo Nordisk (NVO) <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-submits-revised-bid-for-metsera-enters-bidding-war-with-pfizer/cLGFsgdR3x2">announced</a> on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR), following Pfizer's (PFE) agreement to acquire the smaller obesity biopharmaceutical company in September. Metsera has now given Pfizer four business days to negotiate potential adjustments to the existing transaction. The company also noted it would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal.&nbsp;“The best part would be if PFE lets NVO walk away with MTSR rather than up its own bid a few billion dollars, and instead makes a better offer to VKTX,” a Stocktwits user wrote.<stembedurl>https://stocktwits.com/spodero/message/634314721</stembedurl>Another sees Viking ending up with a good deal in time.<stembedurl>https://stocktwits.com/Idvst8/message/634311871</stembedurl>Shares of VKTX traded 10% higher at the time of writing. On Stocktwits, retail sentiment around VKTX stayed within the ‘bullish’ territory while message volume remained at ‘high’ levels.Pfizer was previously developing its own oral weight-loss drug, Danuglipron, but discontinued its development in April 2025 due to liver enzyme elevations in patients. The company is now looking to enter the booming obesity market with an acquisition.<h2 class="st-heading-2">Viking’s Obesity Program</h2>Viking, meanwhile, is evaluating both subcutaneous and oral formulations of its obesity program VK2735 in clinical trials. It is a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both.In early and mid-stage trials, subcutaneous VK2735 demonstrated an encouraging safety and tolerability profile as well as positive signs of clinical benefit.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 4% this year and approximately 46% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-recalls-cybertrucks-for-second-time-in-october-this-time-for-faulty-light-bar/cLGFud9R3xe">Tesla Recalls Cybertrucks For Second Time In October – This Time For A Faulty Light Bar</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera 

Viking and Metsera are both attempting to develop drugs for the treatment of obesity.

<ul class="summary-bullets"><li>Novo has proposed to acquire all outstanding shares of Metsera’s common stock at a price of $56.50 per share in cash and additional milestone payments of up to $21.25 per share.</li><li>Pfizer on Thursday lashed out at the proposal, terming it “reckless,” “unprecedented,” and “illusory.”</li><li>Metsera declared that the Novo Nordisk proposal is “superior” and it may negotiate potential adjustments to the existing Pfizer transaction in light of the new proposal. &nbsp;</li></ul>Danish drugmaker Novo Nordisk (NVO) said on Thursday that it has submitted an unsolicited proposal to acquire Metsera, Inc. (MTSR) after Pfizer (PFE) agreed to acquire the smaller obesity biopharmaceutical company in September.New York City-based Metsera is developing medicines for obesity and cardiometabolic diseases. Novo has <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916443">proposed</a> to acquire all outstanding shares of Metsera’s common stock at a price of $56.50 per share in cash and contingent value rights (CVRs) for up to $21.25 per share in cash, which will be received on the achievement of certain milestones.The company also said that the cash consideration would be paid at signing in exchange for non-voting preferred stock representing 50% of Metsera’s share capital. The CVRs will be issued upon the closing of the acquisition in exchange for the remaining shares, it added.<h2 class="st-heading-2">Pfizer-Metsera Deal</h2>Pfizer had said in September that it would acquire Metsera for $47.50 per share in cash at closing, and contingent value rights (CVR) entitling holders to potential additional payments of up to $22.50 per share in cash tied to three specific clinical and regulatory milestones.Novo is now proposing to buy Metsera for as much as $77.75 per share, compared to Pfizer’s maximum bid value of $70 per share.<h2 class="st-heading-2">Pfizer Hits Back</h2>Pfizer on Thursday<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251030787900/en/Pfizer-Addresses-Proposal-for-Metsera"> lashed</a> out at the proposal, terming it “reckless,” “unprecedented,” and “illusory.”“It is an attempt by a company with a dominant market position to suppress competition in violation of law by taking over an emerging American challenger,” Pfizer said. “The proposal is illusory and cannot qualify as a superior proposal under Pfizer’s agreement with Metsera, and Pfizer is prepared to pursue all legal avenues to enforce its rights under its agreement,” it added.According to Pfizer, Metsera previously rejected Novo Nordisk’s proposal due to “a variety of risks” in its deal structure.<h2 class="st-heading-2">Metsera Responds</h2>Metsera on Thursday <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.metsera.com/news-releases/news-release-details/metsera-receives-unsolicited-proposal-novo-nordisk">declared</a> that the Novo Nordisk proposal is “superior,” and it may negotiate potential adjustments to the existing Pfizer transaction in light of the new offer.Pfizer has the right to negotiate adjustments for four business days from Thursday’s notice, it noted.While Pfizer holds that it does not believe Metsera has the right to deliver this notice, Metsera said that it disagrees. Metsera would be entitled to terminate the Pfizer merger agreement if Novo’s proposal continues to constitute a superior proposal, it said.“At this time, the Pfizer Merger Agreement remains in full effect, and Metsera's Board of Directors reaffirm their recommendation that the holders of Metsera common stock approve the adoption of the Pfizer Merger Agreement and approve the Merger with Pfizer on the terms and subject to the conditions set forth in the Pfizer Merger Agreement,” the company said.However, Semafor <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid">reported</a> on Thursday afternoon, citing a person familiar with the matter, that Pfizer is preparing to sue Metsera and also possibly Novo Nordisk.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/MTSR">MTSR shares</a> traded 20% higher in the pre-market session at the time of writing, while <a href="https://stocktwits.com/symbol/NVO">NVO shares</a> slumped 2%. On Stocktwits, retail sentiment around MTSR jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘low’ to ‘high’ levels.MTSR stock has nearly doubled this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-decline-amid-mixed-big-tech-earnings/cLGFrZmR3DC">Dow Futures Decline Amid Mixed Big Tech Earnings: META, MSFT, GOOGL, AAPL Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.Editor’s Note: The story has been updated with information from a recent report about Pfizer’s potential legal action against Metsera and Novo Nordisk.

In this photo illustration, the Metsera logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer

Novo is now proposing to buy Metsera for as much as $77.75 per share, compared to Pfizer’s maximum bid value of $70 per share.

Metsera Receives Unsolicited Proposal from Novo Nordisk

Metsera Receives Unsolicited Proposal from Novo Nordisk Metsera Receives Unsolicited Proposal from Novo Nordisk PR Newswire NEW YORK, Oct. 30, 2025 Metsera Declares Novo Nordisk Proposal 'Superior...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell on June 29, 2022 and is headquartered in New York, NY.

Metsera Inc.

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MTSR
Metsera Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MTSR News

MTSRMetsera Inc